BioWorld

Oct. 12, 2007

View Archived Issues

Cortex Falls As FDA Rejects CX717 Phase IIb In ADHD

Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today) Read More

Missed Endpoint Won't Doom Future of Gattex, NPS Vows

Read More

CombinatoRx Stock Offering Nets $33M For Thick Pipeline

Read More

Hemispherx Files Ampligen NDA: First Therapy For CFS?

Read More

Pharmaxis Raises $45M To Push Late-Stage Pulmonary Drugs

Read More

CuraGen Shuts Down Program Following 2nd Phase II Failure

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More